RxDoctor Payments Data

Timothy Boyek, MD

Interventional Cardiology · West Chester, PANPI 1275693210

Payments from drug & device makers

$2,230in general payments, 2019–2025

Across 101 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$648
  • Novartis$326
  • Impulse Dynamics (USA) Inc.$180
  • Amgen$139
  • Cleerly, Inc.$127
  • E.r. Squibb & Sons, L.L.C.$121
  • plus $690 from 16 others

What the payments were for

  • Food & beverage$2,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,230 in reported general payments places this provider in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$226,161
Medicare patients
827
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$278,638
Repatha SureclickEvolocumab80$113,375
XareltoRivaroxaban70$89,556
EntrestoSacubitril/Valsartan13$25,231
JardianceEmpagliflozin19$19,482
BrilintaTicagrelor14$17,372
Praluent PenAlirocumab13$14,899
Rosuvastatin Calcium808$14,515
Metoprolol Succinate772$13,068
Ezetimibe310$9,208
Atorvastatin Calcium322$4,664
Valsartan107$3,110
Losartan Potassium192$2,660
Amlodipine Besylate316$1,945
ClopidogrelClopidogrel Bisulfate126$1,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$278,638247 claims
Johnson & JohnsonXarelto$62$89,55670 claims
NovartisEntresto$326$25,23113 claims
Boehringer IngelheimJardiance$109$19,48219 claims
AstraZenecaBrilinta$87$17,37214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →